Clinical trial · Observational
The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma
The Risk of Developing Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma: A SEER-based Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Ewing Sarcoma | Ewing Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The standardized incidence ratio and excess risk of developing acute myeloid leukemia in Ewing's sarcoma patients
- timeFrame
- from Jan, 2000 till Dec, 2021
- description
- The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess absolute risk for acute myeloid leukemia in Ewing's sarcoma patients.
Secondary outcomes (2)
- measure
- The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients across different racial groups
- timeFrame
- from Jan, 2000 till Dec, 2021
- measure
- The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients between different stages
- timeFrame
- from Jan, 2000 till Dec, 2021
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with Ewing sarcoma * Latency exclusion period of 6 months * Sequence 0 or 1 Exclusion Criteria: * patients lacking age documentation or age reported only on death certificates or autopsies
References
Publications (0)
Data not yet available